

Organization	Name of Organization / 会社名
	ToolGen, Inc.
	URL
	http://eng.toolgen.com/
	Brief Descriptions of Organization / 会社概要
	<ul style="list-style-type: none"> - History of innovation: Development of multiple genome editing platforms - Founded in 1999 based on zinc finger technology, ToolGen has been focusing on the development of genome modulating and editing tools. ToolGen developed CRISPR/Cas9-based genome editing technology in 2012. - ToolGen has been developing and generating IPs on the application of CRISPR/Cas9 for the development of better gene and cell therapeutics.

Oral Presentation	Title of Presentation / 講演タイトル
	Development of therapeutic genome editing programs
	Abstract / 要旨
	<p>Innovative genome engineering technology utilizing programmable nucleases enabled a fast and efficient editing of genetic information in various cells and organisms. CRISPR nucleases, recently developed from a prokaryotic adaptive immune system, in particular, provide a robust programmable nuclease platform with high reliability and specificity. In biomedical fields, CRISPR nucleases are expected to enable therapeutic genome editing for many rare hereditary diseases. It can also be used to establish and improve the efficacy and safety of cell therapies for various diseases.</p> <p>ToolGen holds a CRISPR IP portfolio, with one of the earliest priority dates in the field, including multiple issued and pending claims worldwide. ToolGen is developing therapeutic genome editing programs in the field of gene and cell therapy.</p> <p>In this talk, our efforts to improve CRISPR/Cas9 for therapeutic applications will be presented along with the introduction to therapeutic programs in discovery stage.</p>
	Objectives and/or Motives / 目的
<p>Working with partners with compatible capabilities is crucial for the development of therapeutic genome editing programs. We are confident in our expertise in CRISPR/Cas9 and genome editing. We are looking for potential partners with the expertise in development of therapeutics or with compatible technologies in gene and cell therapy.</p> <p>We are open for diverse partnership models from licensing to JV.</p>	